News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
AOL.com Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Wall Street Zen has upgraded Acushnet (NYSE:GOLF) from a "hold" to a "buy" rating, despite the broader analyst consensus remaining "Hold" with an average price target of $99.17. The upgrade follows stronger-than-expected quarterly results, where Acushnet reported EPS of $2.08 against an expected $1.63 …
Acumen Pharmaceuticals (NASDAQ: ABOS) held its Q2 2026 earnings conference call, focusing on the upcoming Phase II ALTITUDE-AD trial results for sabirnetug, expected by late 2026. The company reported $110.2 million in cash and marketable securities, providing liquidity until early 2027, with a net …
(RTTNews) - Acumen Pharmaceuticals Inc. (ABOS), a clinical-stage biopharmaceutical company, on Wednesday announced second quarter financial results and noted a lower net loss owing to reduced research and development (R&D) expenses. The company is engaged in developing novel therapeutics targeting toxic soluble amyloid beta …
(RTTNews) - Abacus Global Management, Inc. (ABX), a financial service provider, said that its board has authorized a $100 million share repurchase program, commencing August 17. This authorization aligns with the company's capital allocation framework. Jay Jackson, CEO of Abacus, said: "This repurchase authorization …
Citi has reiterated its Buy rating for Acumen Pharmaceuticals (ABOS.US) and maintained its target price at $4. This continued endorsement suggests the analyst firm sees ongoing potential or stability in the company's financial outlook and stock performance.
Kayne Anderson Rudnick Investment Management, LLC has disclosed its beneficial ownership of 5,431,452 shares of Acushnet Holdings Corp (GOLF) common stock, representing 9.3% of the outstanding shares as of June 30, 2026. The filing, an amended Schedule 13G, details the firm's sole and shared …
Acushnet Holdings Corp. (NYSE:GOLF) reported strong Q2 2026 results with consolidated net sales up 14.2% on a constant currency basis, driven by equipment momentum and the strategic acceleration of the GTS metals launch. The company raised its full-year guidance for both net sales and …
Handelsbanken Fonder AB reduced its stake in Acuity, Inc. by 11.9% in the second quarter, now holding 43,491 shares valued at $16.38 million. Institutional investors own 98.21% of Acuity's stock, and analysts maintain a "Moderate Buy" rating with a consensus price target of $397.17. …
The 5 Most Interesting Analyst Questions From Acushnet's Q2 Earnings Call Acushnet's second quarter results surpassed Wall Street expectations for both revenue and earnings, yet the market responded negatively, likely reflecting concerns raised on the call about the sustainability of recent growth. Management attributed …
This article reports that Acumen Pharmaceuticals Inc. filed a Form 8K for August 12. The brief announcement provides no further details about the content of the filing. The article is from Investing.com and was published on August 12, 2026.
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Acuity (AYI) continues to attract attention after recently changing its corporate name from Acuity Brands, Inc., a move that highlights its focus on lighting, …
Assenagon Asset Management S.A. significantly reduced its stake in Acuity, Inc. (NYSE:AYI) by 78.9% in the second quarter, selling 56,569 shares but still retaining 15,109 shares valued at approximately $5.7 million. Despite this, Acuity reported strong quarterly earnings of $5.31 per share, exceeding estimates, …
Acushnet Holdings reported a significant increase in Q2 net sales and net income, driven by tariff refunds and strong performance from Titleist golf equipment. The company also raised its full-year 2026 outlook for net sales and adjusted EBITDA. A quarterly dividend of $0.255 per …
Acumen Pharmaceuticals (NASDAQ:ABOS) reported a quarterly loss of $0.45 per share, missing analyst estimates by $0.09. The company expects top-line Phase II ALTITUDE-AD results for sabirnetug in late 2026 and plans to file an IND for a blood-brain-barrier delivery candidate in mid-2027. Acumen ended …
Acumen Pharmaceuticals provided updates on its Q2 earnings call, confirming it is on track to release top-line results in late 2026 for its Phase II ALTITUDE-AD study of sabirnetug, an investigational antibody for early Alzheimer's disease. The company also discussed its enhanced brain delivery …
Wedge Capital Management L L P NC significantly increased its stake in Acuity, Inc. (NYSE:AYI) by 8.8% during the second quarter, bringing its total holdings to 42,944 shares valued at $16.2 million. This move comes as Acuity continues to perform well, exceeding quarterly EPS …
Acuity Brands (AYI): Buy, Sell, or Hold Post Q2 Earnings? Acuity Brands trades at $360.33 and has moved in lockstep with the market. Its shares have returned 17.9% over the last six months while the S&P 500 has gained 13%. Is AYI a buy …
Spartacus Acquisition Corp. II (TMTS), a Cayman Islands SPAC, reported net income of $1,928,284 for Q2 2026 and $2,828,130 for the first half of 2026, primarily driven by interest earned on trust investments. The company's Trust Account held $232,797,250 as of June 30, 2026, …
Spartacus Acquisition Corp. II reported a net income of $1.93 million for Q2 2026, with diluted EPS of $0.06. This income is primarily from interest generated by its $230 million trust account, as the blank-check company is actively seeking a business combination within the …
Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 5:00 p.m. ET CALL PARTICIPANTS Head of Investor Relations - David JacksonChairman and Chief Executive Officer - Jay JacksonChief Investment Officer - Elena PlescoChief Financial and Chief Operating Officer - William McCauley TAKEAWAYS …
Search by ticker symbol or company name and select a result to open its chart.